Long-Acting Injectables (LAIs) Market Size to Hit USD 57.26 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Long-Acting Injectables (LAIs) Market

5.1. COVID-19 Landscape: Long-Acting Injectables (LAIs) Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Long-Acting Injectables (LAIs) Market, By Drug Type

8.1. Long-Acting Injectables (LAIs) Market Revenue and Volume, by Drug Type

8.1.1. Antipsychotics

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Hormonal Agents

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Anti-Infectives

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Pain Management Drugs

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Long-Acting Injectables (LAIs) Market, By Delivery Technology

9.1. Long-Acting Injectables (LAIs) Market Revenue and Volume, by Delivery Technology

9.1.1. Microsphere-Based Systems

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Liposome-Based Systems

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Polymer-Based Depots

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. In-Situ Forming Gels

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. nanoparticle-based systems

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Others (e.g., crystalline suspensions, oil-based depots)

9.1.6.1. Market Revenue and Volume Forecast

Chapter 10. Global Long-Acting Injectables (LAIs) Market, By Route of Administration

10.1. Long-Acting Injectables (LAIs) Market Revenue and Volume, by Route of Administration

10.1.1. Intramuscular (IM)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Subcutaneous (SC)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Intradermal (ID)

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Others (e.g., intra-articular, intravitreal)

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Long-Acting Injectables (LAIs) Market, By Indication

11.1. Long-Acting Injectables (LAIs) Market Revenue and Volume, by Indication

11.1.1. Schizophrenia

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Bipolar Disorder

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Major Depressive Disorder (MDD)

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Contraception

11.1.4.1. Market Revenue and Volume Forecast

11.1.5. Hormone Deficiency Disorders

11.1.5.1. Market Revenue and Volume Forecast

11.1.6. HIV/AIDS

11.1.6.1. Market Revenue and Volume Forecast

11.1.7. Pain Management

11.1.7.1. Market Revenue and Volume Forecast

11.1.8. Oncology

11.1.8.1. Market Revenue and Volume Forecast

11.1.9. Others (e.g., opioid addiction, chronic inflammatory diseases)

11.1.9.1. Market Revenue and Volume Forecast

Chapter 12. Global Long-Acting Injectables (LAIs) Market, By Patient Group

12.1. Long-Acting Injectables (LAIs) Market Revenue and Volume, by Patient Group

12.1.1. Adults

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Pediatrics

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Geriatrics

12.1.3.1. Market Revenue and Volume Forecast

Chapter 13. Global Long-Acting Injectables (LAIs) Market, By Distribution Channel

13.1. Long-Acting Injectables (LAIs) Market Revenue and Volume, by Distribution Channel

13.1.1. Hospital Pharmacies

13.1.1.1. Market Revenue and Volume Forecast

13.1.2. Retail Pharmacies

13.1.2.1. Market Revenue and Volume Forecast

13.1.3. Online Pharmacies

13.1.3.1. Market Revenue and Volume Forecast

13.1.3. Others (e.g., specialty clinics)

13.1.3.1. Market Revenue and Volume Forecast

Chapter 14. Global Long-Acting Injectables (LAIs) Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Volume Forecast, by Drug Type

14.1.2. Market Revenue and Volume Forecast, by Delivery Technology

14.1.3. Market Revenue and Volume Forecast, by Route of Administration

14.1.4. Market Revenue and Volume Forecast, by Indication

14.1.5. Market Revenue and Volume Forecast, by Patient Group

14.1.6. Market Revenue and Volume Forecast, by Distribution Channel

14.1.7. U.S.

14.1.7.1. Market Revenue and Volume Forecast, by Drug Type

14.1.7.2. Market Revenue and Volume Forecast, by Delivery Technology

14.1.7.3. Market Revenue and Volume Forecast, by Route of Administration

14.1.7.4. Market Revenue and Volume Forecast, by Indication

14.1.8. Market Revenue and Volume Forecast, by Patient Group

14.1.8.1. Market Revenue and Volume Forecast, by Distribution Channel

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Volume Forecast, by Drug Type

14.1.9.2. Market Revenue and Volume Forecast, by Delivery Technology

14.1.9.3. Market Revenue and Volume Forecast, by Route of Administration

14.1.9.4. Market Revenue and Volume Forecast, by Indication

14.1.10. Market Revenue and Volume Forecast, by Patient Group

14.1.11. Market Revenue and Volume Forecast, by Distribution Channel

14.2. Europe

14.2.1. Market Revenue and Volume Forecast, by Drug Type

14.2.2. Market Revenue and Volume Forecast, by Delivery Technology

14.2.3. Market Revenue and Volume Forecast, by Route of Administration

14.2.4. Market Revenue and Volume Forecast, by Indication

14.2.5. Market Revenue and Volume Forecast, by Patient Group

14.2.6. Market Revenue and Volume Forecast, by Distribution Channel

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Volume Forecast, by Drug Type

14.2.8.2. Market Revenue and Volume Forecast, by Delivery Technology

14.2.8.3. Market Revenue and Volume Forecast, by Route of Administration

14.2.9. Market Revenue and Volume Forecast, by Indication

14.2.10. Market Revenue and Volume Forecast, by Patient Group

14.2.10.1. Market Revenue and Volume Forecast, by Distribution Channel

14.2.11. Germany

14.2.11.1. Market Revenue and Volume Forecast, by Drug Type

14.2.11.2. Market Revenue and Volume Forecast, by Delivery Technology

14.2.11.3. Market Revenue and Volume Forecast, by Route of Administration

14.2.12. Market Revenue and Volume Forecast, by Indication

14.2.13. Market Revenue and Volume Forecast, by Patient Group

14.2.14. Market Revenue and Volume Forecast, by Distribution Channel

14.2.15. France

14.2.15.1. Market Revenue and Volume Forecast, by Drug Type

14.2.15.2. Market Revenue and Volume Forecast, by Delivery Technology

14.2.15.3. Market Revenue and Volume Forecast, by Route of Administration

14.2.15.4. Market Revenue and Volume Forecast, by Indication

14.2.16. Market Revenue and Volume Forecast, by Patient Group

14.2.16.1. Market Revenue and Volume Forecast, by Distribution Channel

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Volume Forecast, by Drug Type

14.2.17.2. Market Revenue and Volume Forecast, by Delivery Technology

14.2.17.3. Market Revenue and Volume Forecast, by Route of Administration

14.2.17.4. Market Revenue and Volume Forecast, by Indication

14.2.18. Market Revenue and Volume Forecast, by Patient Group

14.2.18.1. Market Revenue and Volume Forecast, by Distribution Channel

14.3. APAC

14.3.1. Market Revenue and Volume Forecast, by Drug Type

14.3.2. Market Revenue and Volume Forecast, by Delivery Technology

14.3.3. Market Revenue and Volume Forecast, by Route of Administration

14.3.4. Market Revenue and Volume Forecast, by Indication

14.3.5. Market Revenue and Volume Forecast, by Patient Group

14.3.6. Market Revenue and Volume Forecast, by Distribution Channel

14.3.7. India

14.3.7.1. Market Revenue and Volume Forecast, by Drug Type

14.3.7.2. Market Revenue and Volume Forecast, by Delivery Technology

14.3.7.3. Market Revenue and Volume Forecast, by Route of Administration

14.3.7.4. Market Revenue and Volume Forecast, by Indication

14.3.8. Market Revenue and Volume Forecast, by Patient Group

14.3.9. Market Revenue and Volume Forecast, by Distribution Channel

14.3.10. China

14.3.10.1. Market Revenue and Volume Forecast, by Drug Type

14.3.10.2. Market Revenue and Volume Forecast, by Delivery Technology

14.3.10.3. Market Revenue and Volume Forecast, by Route of Administration

14.3.10.4. Market Revenue and Volume Forecast, by Indication

14.3.11. Market Revenue and Volume Forecast, by Patient Group

14.3.11.1. Market Revenue and Volume Forecast, by Distribution Channel

14.3.12. Japan

14.3.12.1. Market Revenue and Volume Forecast, by Drug Type

14.3.12.2. Market Revenue and Volume Forecast, by Delivery Technology

14.3.12.3. Market Revenue and Volume Forecast, by Route of Administration

14.3.12.4. Market Revenue and Volume Forecast, by Indication

14.3.12.5. Market Revenue and Volume Forecast, by Patient Group

14.3.12.6. Market Revenue and Volume Forecast, by Distribution Channel

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Volume Forecast, by Drug Type

14.3.13.2. Market Revenue and Volume Forecast, by Delivery Technology

14.3.13.3. Market Revenue and Volume Forecast, by Route of Administration

14.3.13.4. Market Revenue and Volume Forecast, by Indication

14.3.13.5. Market Revenue and Volume Forecast, by Patient Group

14.3.13.6. Market Revenue and Volume Forecast, by Distribution Channel

14.4. MEA

14.4.1. Market Revenue and Volume Forecast, by Drug Type

14.4.2. Market Revenue and Volume Forecast, by Delivery Technology

14.4.3. Market Revenue and Volume Forecast, by Route of Administration

14.4.4. Market Revenue and Volume Forecast, by Indication

14.4.5. Market Revenue and Volume Forecast, by Patient Group

14.4.6. Market Revenue and Volume Forecast, by Distribution Channel

14.4.7. GCC

14.4.7.1. Market Revenue and Volume Forecast, by Drug Type

14.4.7.2. Market Revenue and Volume Forecast, by Delivery Technology

14.4.7.3. Market Revenue and Volume Forecast, by Route of Administration

14.4.7.4. Market Revenue and Volume Forecast, by Indication

14.4.8. Market Revenue and Volume Forecast, by Patient Group

14.4.9. Market Revenue and Volume Forecast, by Distribution Channel

14.4.10. North Africa

14.4.10.1. Market Revenue and Volume Forecast, by Drug Type

14.4.10.2. Market Revenue and Volume Forecast, by Delivery Technology

14.4.10.3. Market Revenue and Volume Forecast, by Route of Administration

14.4.10.4. Market Revenue and Volume Forecast, by Indication

14.4.11. Market Revenue and Volume Forecast, by Patient Group

14.4.12. Market Revenue and Volume Forecast, by Distribution Channel

14.4.13. South Africa

14.4.13.1. Market Revenue and Volume Forecast, by Drug Type

14.4.13.2. Market Revenue and Volume Forecast, by Delivery Technology

14.4.13.3. Market Revenue and Volume Forecast, by Route of Administration

14.4.13.4. Market Revenue and Volume Forecast, by Indication

14.4.13.5. Market Revenue and Volume Forecast, by Patient Group

14.4.13.6. Market Revenue and Volume Forecast, by Distribution Channel

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Volume Forecast, by Drug Type

14.4.14.2. Market Revenue and Volume Forecast, by Delivery Technology

14.4.14.3. Market Revenue and Volume Forecast, by Route of Administration

14.4.14.4. Market Revenue and Volume Forecast, by Indication

14.4.14.5. Market Revenue and Volume Forecast, by Patient Group

14.4.14.6. Market Revenue and Volume Forecast, by Distribution Channel

14.5. Latin America

14.5.1. Market Revenue and Volume Forecast, by Drug Type

14.5.2. Market Revenue and Volume Forecast, by Delivery Technology

14.5.3. Market Revenue and Volume Forecast, by Route of Administration

14.5.4. Market Revenue and Volume Forecast, by Indication

14.5.5. Market Revenue and Volume Forecast, by Patient Group

14.5.6. Market Revenue and Volume Forecast, by Distribution Channel

14.5.7. Brazil

14.5.7.1. Market Revenue and Volume Forecast, by Drug Type

14.5.7.2. Market Revenue and Volume Forecast, by Delivery Technology

14.5.7.3. Market Revenue and Volume Forecast, by Route of Administration

14.5.7.4. Market Revenue and Volume Forecast, by Indication

14.5.8. Market Revenue and Volume Forecast, by Patient Group

14.5.8.1. Market Revenue and Volume Forecast, by Distribution Channel

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Volume Forecast, by Drug Type

14.5.9.2. Market Revenue and Volume Forecast, by Delivery Technology

14.5.9.3. Market Revenue and Volume Forecast, by Route of Administration

14.5.9.4. Market Revenue and Volume Forecast, by Indication

14.5.9.5. Market Revenue and Volume Forecast, by Patient Group

14.5.9.6. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 15. Company Profiles

15.1. Johnson & Johnson (Janssen Pharmaceuticals)

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Pfizer Inc.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Eli Lilly and Company

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Teva Pharmaceutical Industries Ltd.

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. AstraZeneca PLC

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Novartis AG

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Alkermes plc

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Sanofi S.A.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. ViiV Healthcare

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. GSK plc

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The long-acting injectables (LAIs) market size is expected to increase from USD 16.94 billion in 2024 to USD 57.26 billion by 2034.

The long-acting injectables (LAIs) market is expected to grow at a compound annual growth rate (CAGR) of around 12.95% from 2025 to 2034.

The major players in the long-acting injectables (LAIs) market include Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca PLC, Novartis AG, Alkermes plc, Sanofi S.A., ViiV Healthcare, GSK plc, AbbVie Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Bayer AG, Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Viatris Inc.

The driving factors of the long-acting injectables (LAIs) market are the improved adherence, reduced dosing frequency, and providing stable pharmacokinetics for chronic and specialty conditions. Also, an obvious reason for this rise is the advancement in drug delivery systems.

North America region will lead the global long-acting injectables (LAIs) market during the forecast period 2025 to 2034.